Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates

被引：85
作者：
Buehrle, Deanna J. [1 ]
Shields, Ryan K. [2 ,3 ]
Chen, Liang [4 ]
Hao, Binghua [3 ]
Press, Ellen G. [2 ]
Alkrouk, Ammar [2 ]
Potoski, Brian A. [1 ]
Kreiswirth, Barry N.
Clancy, Cornelius J. [2 ,3 ,5 ]
Nguyen, M. Hong [2 ,3 ]
机构：
[1] Univ Pittsburgh, Dept Pharm & Therapeut, Pittsburgh, PA USA
[2] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA
[3] Univ Pittsburgh, Med Ctr, XDR Pathogen Lab, Pittsburgh, PA USA
[4] Rutgers State Univ, Sch Med, Newark, NJ 07102 USA
[5] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2016年 / 60卷 / 05期
基金：
美国国家卫生研究院;
关键词：
BETA-LACTAM RESISTANCE; BLOOD-STREAM INFECTIONS; GRAM-NEGATIVE ORGANISMS; US MEDICAL-CENTERS; CARBAPENEM RESISTANCE; KLEBSIELLA-PNEUMONIAE; MEDITERRANEAN COUNTRIES; CXA-101; FR264205; MECHANISMS; ENTEROBACTERIACEAE;
D O I：
10.1128/AAC.02969-15
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
We compared ceftazidime-avibactam, ceftolozane-tazobactam, ceftazidime, cefepime, and piperacillin-tazobactam MICs for 38 meropenem-resistant Pseudomonas aeruginosa isolates. No isolates harbored carbapenemases; 74% were oprD mutants. Ceftazidime-avibactam and ceftolozane-tazobactam were active against 92% of the isolates, including 80% that were resistant to all three beta-lactams. Forty-three percent of ceftazidime-avibactam-susceptible isolates and 6% of ceftolozane-tazobactam-susceptible isolates exhibited MICs at the respective breakpoints. Ceftolozane-tazobactam and ceftazidime-avibactam are therapeutic options for meropenem-resistant P. aeruginosa infections that should be used judiciously to preserve activity.
引用
收藏
页码：3227 / 3231
页数：5
相关论文
共 25 条
  • [1] In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae
    Aktas, Z.
    Kayacan, C.
    Oncul, O.
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2012, 39 (01) : 86 - 89
  • [2] In Vivo Comparison of CXA-101 (FR264205) with and without Tazobactam versus Piperacillin-Tazobactam Using Human Simulated Exposures against Phenotypically Diverse Gram-Negative Organisms
    Bulik, Catharine C.
    Tessier, Pamela R.
    Keel, Rebecca A.
    Sutherland, Christina A.
    Nicolaua, David P.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (01) : 544 - 549
  • [3] In Vitro Potency of CXA-101, a Novel Cephalosporin, against Pseudomonas aeruginosa Displaying Various Resistance Phenotypes, Including Multidrug Resistance
    Bulik, Catharine C.
    Christensen, Henry
    Nicolau, David P.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (01) : 557 - 559
  • [4] Evaluation of Clonality and Carbapenem Resistance Mechanisms among Acinetobacter baumannii-Acinetobacter calcoaceticus Complex and Enterobacteriaceae Isolates Collected in European and Mediterranean Countries and Detection of Two Novel β-Lactamases, GES-22 and VIM-35
    Castanheira, Mariana
    Costello, Sarah E.
    Woosley, Leah N.
    Deshpande, Lalitagauri M.
    Davies, Todd A.
    Jones, Ronald N.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (12) : 7358 - 7366
  • [5] Mutation-Driven β-Lactam Resistance Mechanisms among Contemporary Ceftazidime-Nonsusceptible Pseudomonas aeruginosa Isolates from US Hospitals
    Castanheira, Mariana
    Mills, Janet C.
    Farrell, David J.
    Jones, Ronald N.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (11) : 6844 - 6850
  • [6] Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-11 in 14 European and Mediterranean countries
    Castanheira, Mariana
    Deshpande, Lalitagauri M.
    Costello, Andrew
    Davies, Todd A.
    Jones, Ronald N.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (07) : 1804 - 1814
  • [7] Clinical and Laboratory Standards Institute, 2014, M100S24 CLIN LAB STA
  • [8] Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases
    Ehmann, David E.
    Jahic, Haris
    Ross, Philip L.
    Gu, Rong-Fang
    Hu, Jun
    Durand-Reville, Thomas F.
    Lahiri, Sushmita
    Thresher, Jason
    Livchak, Stephania
    Gao, Ning
    Palmer, Tiffany
    Walkup, Grant K.
    Fisher, Stewart L.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (39) : 27960 - 27971
  • [9] Beta-Lactam Resistance Mechanisms in Pseudomonas aeruginosa Strains Causing Bloodstream Infections: Comparative Results Between Brazilian and American Isolates
    Fehlberg, Lorena C. C.
    Xavier, Danilo E.
    Peraro, Paula P.
    Marra, Alexandre R.
    Edmond, Michael B.
    Gales, Ana C.
    [J]. MICROBIAL DRUG RESISTANCE, 2012, 18 (04) : 402 - 407
  • [10] Molecular mechanisms of β-lactam resistance in carbapenemase-producing Klebsiella pneumoniae from Sri Lanka
    Hall, Jarrad M.
    Corea, Enoka
    Sanjeewani, H. D. Anusha
    Inglis, Timothy J. J.
    [J]. JOURNAL OF MEDICAL MICROBIOLOGY, 2014, 63 : 1087 - 1092
123